scout

Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

Articles by Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

Charting the Future: Key Therapies for Managing EGFR-Mutant NSCLC

ByJonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago,Hatim Husain, MD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center,Julia K. Rotow, MD

This episode focuses on exploring additional therapeutic options for managing previously treated advanced or metastatic EGFR-mutated NSCLC, highlighting strategies to optimize patient survival across various stages of disease progression.

Navigating Treatment Choices: Clinically Meaningful Outcomes to Look for in HERTHENA-Lung02

ByJonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago,Hatim Husain, MD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center,Julia K. Rotow, MD

This episode discusses the desired outcomes from the HERTHENA-Lung02 trial that would justify using HER3-DXd before platinum and pemetrexed chemotherapy while also exploring the potential benefits of amivantamab, including its PFS advantage and the observed trend toward improved OS in this treatment setting.

HERTHENA-Lung02 Trial: Exploring the Role of Patritumab Deruxtecan in Advanced EGFR-Mutant NSCLC

ByJonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago,Hatim Husain, MD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center,Julia K. Rotow, MD

This episode summarizes the HERTHENA-Lung02 trial and examines the average duration of response to platinum-based chemotherapy in patients with advanced EGFR-mutated NSCLC who have previously undergone multiple lines of EGFR TKI therapy, discusses strategies for community oncologists to tackle diverse resistance mechanisms to third-generation TKIs, and evaluates the importance of tolerability in sparing platinum-based chemotherapy compared with using ADCs in subsequent treatment lines.

Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice

ByJonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago,Hatim Husain, MD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center,Julia K. Rotow, MD

This episode explores management strategies for hematologic toxicities arising within the first 3 weeks of treatment with HER3-DXd, discusses the potential integration of HER3-DXd into clinical practice upon approval, and identifies unmet needs and suitable patient populations for future clinical trials evaluating HER3-DXd based on insights from the HERTHENA-Lung01 trial results.

Evaluating Response Rates in HERTHENA-Lung01: Insights on HER3-DXd

ByJonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago,Hatim Husain, MD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center,Julia K. Rotow, MD

This episode reviews the response rates reported in the HERTHENA-Lung01 trial among patients with advanced NSCLC exhibiting various resistance mechanisms, evaluates the clinical significance of responses to HER3-DXd based on HER3 expression scores, discusses the relevance of the reported overall DOR, median PFS, and OS, and examines the CNS ORR among patients with baseline brain metastases in relation to the ORRs.

Adverse Event Management and Resistance Mechanisms: Key Considerations for Datopotamab Deruxtecan in Advanced NSCLC

ByJonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago,Hatim Husain, MD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center,Julia K. Rotow, MD

This episode addresses strategies for mitigating and managing adverse events associated with Dato-DXd in patients with advanced NSCLC, explores how the drug’s structure may help prevent acquired resistance mechanisms that are common with TKIs, and discusses the broader implications of integrating Dato-DXd and other ADCs into the treatment landscape for this patient population.

Impressions From TROPION-Lung05: Dato-DXd in Heavily Pretreated Advanced NSCLC

ByJonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago,Hatim Husain, MD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center,Julia K. Rotow, MD

This episode discusses the impressive ORR of more than 40% from the phase 2 TROPION-Lung05 trial of Dato-DXd in patients with EGFR-mutated advanced NSCLC, its clinical impact on those treated with 3 or more prior therapies, and explores the potential of Dato-DXd as a practice-changing therapy, given the median DOR of 7 months and DCR of 79%.

Managing Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management Strategies

ByJonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago,Hatim Husain, MD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center,Julia K. Rotow, MD

This episode examines the management of ILD/pneumonitis associated with TROP2-directed ADCs in patients with advanced NSCLC and strategies for mitigating these risks, addresses hematologic toxicities related to docetaxel, and discusses the improved tolerability and lower incidence of severe treatment-emergent adverse events with Dato-DXd compared with docetaxel.

Role of Datopotamab Deruxtecan in Advanced NSCLC: Insights From TROPION-Lung01

ByJonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago,Hatim Husain, MD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center,Julia K. Rotow, MD

This episode covers current sequencing strategies for NSCLC after targeted therapies and platinum chemotherapy, discusses the COMPEL trial with osimertinib, reviews OS and PFS end points from the TROPION-Lung01 study, examines hypotheses behind differential PFS responses in nonsquamous vs squamous NSCLC, and addresses what constitutes a clinically meaningful, durable response in heavily pretreated patients with advanced NSCLC and actionable genomic alterations.

Targeted ADCs vs Chemotherapy in Heavily Pretreated NSCLC: Clinical Benefits and Challenges

ByJonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago,Hatim Husain, MD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center,Julia K. Rotow, MD

This episode discusses the urgent need for more effective and tolerable therapies for patients with EGFR-mutated NSCLC who have exhausted targeted treatments, comparing the clinical benefits of a targeted ADC approach vs chemotherapy, with a focus on the TROPION-Lung01 study of Dato-DXd vs docetaxel for heavily pretreated advanced/metastatic NSCLC with actionable genomic alterations.

Tailoring Treatment by Stage: Insights From ADAURA for Stage IB to IIIA EGFR-Mutated NSCLC

ByJonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago,Hatim Husain, MD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center,Julia K. Rotow, MD

This episode highlights the significance of third-generation EGFR TKIs in delaying subsequent therapies for resectable, stage IB to IIIA EGFR-mutated NSCLC, explores the risks of postresection treatments for disease progression, and discusses treatment considerations for patients across different stages, focusing on the ADAURA trial outcomes for stage IB to IIIA NSCLC.

Osimertinib in Resected Stage IB to IIIA NSCLC: Perspectives on Its Use for Less Common EGFR Mutations

ByJonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago,Hatim Husain, MD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center,Julia K. Rotow, MD

Although the NCCN guidelines recommend osimertinib as an adjuvant therapy option, what is your position on its use for completely resected stage IB to IIIA NSCLC with less common EGFR activating mutations, such as exon 20 insertion?

ADAURA Trial Findings: Outcomes and CNS Involvement in EGFR-Mutated NSCLC

ByJonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago,Hatim Husain, MD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center,Julia K. Rotow, MD

This episode reviews the key takeaways from the ADAURA trial, discusses strategies for protecting the CNS in EGFR-mutated NSCLC, and examines the impact ADAURA had on recurrence rates in patients with completely resected EGFR-mutated NSCLC who were previously treated with adjuvant chemotherapy.

Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA

ByJonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago,Hatim Husain, MD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center,Julia K. Rotow, MD

This episode delves into expert perspectives on the safety and tolerability of combining osimertinib with chemotherapy in untreated, advanced EGFR-mutated NSCLC, resistance to third-generation EGFR TKIs, the superiority of concurrent versus sequential therapy from the FLAURA2 study, the role of ctDNA in managing additional EGFR mutations, and decision-making in utilizing FLAURA2 for treatment selection.

Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC

ByJonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago,Hatim Husain, MD,Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center,Julia K. Rotow, MD

This episode explores expert insights on the clinical use of osimertinib in the frontline setting for EGFR-mutated NSCLC, the impact of combining osimertinib with platinum-based chemotherapy on progression-free survival (PFS), and the significance of extending PFS by nearly 9 months in patients with advanced NSCLC who are not candidates for curative treatment.

Latest Updated Articles